Shaanxi BLOOM Tech Co., Ltd. yog ib qho ntawm cov tuam ntxhab thiab cov muag khoom ntawm kev txhaj tshuaj aviptadil hauv Suav teb. Txais tos rau kev lag luam wholesale bulk zoo txhaj tshuaj aviptadil rau muag ntawm no los ntawm peb lub hoobkas. Kev pabcuam zoo thiab tus nqi tsim nyog muaj.
Raws li hom hluavtaws peptide nrog tshwj xeeb physiological kev ua haujlwm,kev txhaj tshuaj aviptadilqhia tshwj xeeb thiab tseem ceeb ua tau zoo hauv kev tswj cov kab mob pulmonary vascular. Nws lub hom phiaj tseem ceeb yog tsom ntsoov rau kev tswj hwm diastolic ntawm cov hlab ntsha pulmonary, paub qhov txawv ntawm cov yam ntxwv ua haujlwm dav dav ntawm cov pa vasoactive tshuaj.
Cov khoom no, nrog rau nws cov yam ntxwv tshwj xeeb, tuaj yeem txheeb xyuas thiab ua raws li cov qauv ntawm cov hlab ntsha pulmonary, zam tsis yog - tshwj xeeb ua kom cov hlab ntsha hauv lwm qhov ntawm lub cev, yog li ua tiav lub cev txo qis ntawm pulmonary arterial siab thiab kev ua kom zoo tshaj plaws ntawm pulmonary ntshav ncig txoj hauv kev.
Peb Cov Qauv Khoom
Aviptadil COA
 |
||
| Certificate of Analysis | ||
| Compound npe | Aviptadil | |
| Qib | Pharmaceutical qib | |
| CAS Nr. | 40077-57-4 | |
| Ntau | 36g | |
| Ntim txheem | PE hnab + Al foil hnab | |
| Chaw tsim tshuaj paus | Shaanxi BLOOM TECH Co., Ltd | |
| Ntau No. | 202501090066 | |
| MFG | Peb 9, 2025 | |
| EXP | Peb 8, 2028 | |
| Qauv |
|
|
| Yam khoom | Enterprise txheem | Kev txheeb xyuas qhov tshwm sim |
| Qhov tshwm sim | Dawb los yog yuav luag dawb hmoov | Ua raws |
| Cov ntsiab lus dej | Tsawg dua lossis sib npaug li 5.0% | 0.54% |
| Poob rau ziab | Tsawg dua lossis sib npaug li 1.0% | 0.42% |
| Hnyav Hlau | Pb Tsawg dua lossis sib npaug li 0.5ppm | N.D. |
| Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Hg Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Cd Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Purity (HPLC) | Ntau dua lossis sib npaug li 99.0% | 99.98% |
| Ib qho impurity | <0.8% | 0.52% |
| Tag nrho microbial suav | Tsawg dua lossis sib npaug li 750cfu / g | 95 |
| E. Coli | Tsawg dua lossis sib npaug li 2MPN / g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (los ntawm GC) | Tsawg dua lossis sib npaug li 5000ppm | 500ppm ua |
| Cia | Khaws rau hauv qhov chaw kaw, tsaus, thiab qhuav hauv qab -20 degree | |
|
|
||
|
|
||
| Tshuaj Formula | C147H238N44O42S |
| Exact Mass | 3323.76 |
| Molecular Luj | 3325.85 |
| m/z | 3324.76 (100.0%), 3323.76 (62.9%), 3325.76 (52.1%), 3326.77 (41.3%), 3325.76 (26.9%), 3325.76 (15.1%), 3324.75 (9.5%), 3327.77 (9.4%), 3326.76 (8.6%), 3326.76 (7.9%), 3327.77 (6.7%), 3325.76 (5.4%), 3327.76 (5.4%), 3326.76 (4.7%), 3326.76 (4.5%), 3327.77 (4.5%), 3328.77 (3.6%), 3328.77 (3.1%), 3325.75 (2.8%), 3325.77 (2.7%), 3327.76 (2.4%), 3327.77 (2.3%), 3326.77 (2.2%), 3328.77 (1.9%), 3324.76 (1.7%), 3325.76 (1.6%), 3328.76 (1.5%), 3328.77 (1.5%), 3327.76 (1.3%), 3327.76 (1.3%), 3327.76 (1.2%), 3328.77 (1.1%), 3326.75 (1.1%), 3325.76 (1.1%), 3324.76 (1.0%) |
| Elemental Analysis | C, 53.09; H, 7.21; N, 18.53; O, 20.20; S, 0.96 |
Piv nrog rau lwm cov vasodilators zoo sib xws, qhov no muaj ntau hom phiaj ntawm kev ua, thiab nws cov kev tswj hwm ntau yam tsis yog tsuas yog cuam tshuam nrog kev siv thiab lub sijhawm ntawm vasodilation, tab sis kuj nyob rau hauv nws cov kev cai sib koom ua ke ntawm pulmonary vascular microenvironment. Qhov tshwj xeeb zoo ntawm kev ua no ua rau nws yog ib qho tseem ceeb ntawm kev tswj hwm ntawm pulmonary vascular physiology thiab pathology, thiab nws cov txheej txheem tshwj xeeb ntawm kev ua thiab kev ua tau zoo ntau yam tsim nyog tau txais kev tshawb nrhiav ntxiv thiab kev txhais lus.
Raws li lub hub tseem ceeb rau kev sib pauv roj thiab cov ntshav ncig hauv lub cev, vascular homeostasis ntawm lub ntsws ncaj qha txiav txim siab txog kev ua haujlwm ntawm pulmonary physiological functions. Nws muab kev txhawb nqa tseem ceeb rau kev txhim kho kev ua haujlwm ntawm lub ntsws pauv roj, tshem tawm cov khoom pov tseg raws sij hawm, thiab cov khoom noj khoom haus rau lub ntsws cov ntaub so ntswg los ntawm kev tswj hwm pulmonary vasodilation, zoo tswj lub zog homeostasis ntawm lub ntsws ntsig txog kev ua haujlwm ntawm lub cev.
Targeted yam ntxwv ntawm pulmonary vasodilation
Cov nyhuv vasodilation ntawmkev txhaj tshuaj aviptadilnyob rau hauv cov hlab ntsha pulmonary tsis yog ib tug generalized nyhuv, tab sis muaj ib tug high℃ntawm lub hom phiaj xaiv, uas ua rau nws mus precisely lub pulmonary vascular system thiab txo cov uas tsis yog - tshwj xeeb cuam tshuam rau cov hlab ntsha nyob rau hauv lwm qhov chaw ntawm lub cev. Tshwj xeeb, nws lub hom phiaj yog feem ntau cuam tshuam hauv peb yam:
Ib qho yog qhov tshwj xeeb ntawm qhov chaw ua haujlwm. Piv nrog rau ntau cov hlab ntsha hauv lub cev, cov khoom no muaj txiaj ntsig zoo rau ntau theem ntawm cov hlab ntsha hauv lub ntsws, tshwj xeeb tshaj yog nyob rau hauv cov hlab ntsha tseem ceeb uas koom nrog hauv kev sib pauv roj ntsws xws li pulmonary arterioles thiab pulmonary capillaries. Nws muaj zog lub hom phiaj so thiab tuaj yeem so sai sai vascular phab ntsa nro.
Qhov thib ob yog qhov tshwj xeeb ntawm receptor khi. Nws tsim cov phiaj xwm khi nrog cov receptors tshwj xeeb rau ntawm phab ntsa vascular pulmonary, ua rau receptor-txoj kev teeb tsa kev sib kho, yog li inhibiting kev ua haujlwm ntawm cov leeg nqaij leeg thiab txhawb nqa nruab nrab dilation ntawm vascular lumen. Hom kev khi no tuaj yeem tiv thaiv kev cuam tshuam nrog lwm cov vascular receptors thiab txhim kho qhov tseeb ntawm qhov kev txiav txim.
Qhov thib peb yog hierarchical xwm ntawm qhov kev txiav txim. Nws tuaj yeem ua rau muaj kev cuam tshuam rau cov hlab ntsha ntawm ntau theem hauv lub ntsws, los ntawm kev so me ntsis ntawm cov hlab ntsha pulmonary mus rau qhov tseem ceeb ntawm kev so ntawm pulmonary arterioles, thiab tom qab ntawd mus rau nruab nrab dilation ntawm pulmonary capillaries, tsim ntau - theem thiab tag nrho - puag ncig cov qauv ntawm pulmonary vascular so, seulmonary txhim kho lub hauv paus.
Cov ntaub ntawv saum toj no yog muab los ntawm:
Nazzareno Galie. Cov teebmeem ntawm Inhaled Aviptadil (Vasoactive Intestinal Peptide) Hauv Cov Neeg Mob Pulmonary Arterial Hypertension (PAH). American Journal of Respiratory and Critical Care Medicine, 2010, 181: A2516
Txoj kev nyem ntawm pulmonary arterial hypertension
Qhov txawv txav ntawm pulmonary arterial siab yog qhov tseem ceeb ua rau muaj kev cuam tshuam ntawm pulmonary ntshav ncig, thiabkev txhaj tshuaj aviptadiltuaj yeem txo cov kab mob pathological no tau zoo los ntawm ntau-txoj kev sib koom ua ke, ua tiav kev tswj lub cev ntawm lub ntsws hlab ntsha.
01.Core siab tswj mechanism.
Cov tshuaj no ua rau cov hlab ntsha hauv lub ntsws, ua kom lub cev loj dua ntawm cov hlab ntsha lumen, txo cov kev tiv thaiv thaum cov ntshav ntws los ntawm cov hlab ntsha pulmonary, thiab yog li rhuav tshem cov kab mob pathological ntawm "vascular stenosis siab nce ntshav txaus stagnation", txhawb kev txo qis ntawm pulmonary artery siab mus rau qhov qub;
02.Optimization ntawm pulmonary ncig kuj.
Kev cog lus ntau dhau ntawm pulmonary vascular du leeg yog qhov tseem ceeb ua rau muaj zog pulmonary ncig ua haujlwm.Txhaj tshuaj aveptadiltuaj yeem cuam tshuam qhov sib txawv ntawm cov leeg nqaij pob txha, txo cov vascular phab ntsa nro, txhim kho endothelial permeability, txo cov kev pheej hmoo ntawm intravascular thrombosis, ntxiv txo peripheral tsis kam ntawm pulmonary ncig, thiab muab kev pab txhawb rau kev tswj siab;
03.Synergistic kev tswj ntawm vascular endothelial yam.
Nws tuaj yeem tswj hwm qhov tso tawm ntawm cov khoom hauv pulmonary vascular endothelial hlwb, txhawb kev tso tawm vasodilator yam, inhibit tiam ntawm vasoconstrictor yam, thiab ntxiv txhim kho cov vasodilation ntawm cov hlab ntsha pulmonary los ntawm qhov kev tswj xyuas qhov sib npaug, ua kom muaj kev sib koom ua ke ntawm pulmonary arterial hypertension thiab tsis txhob muaj kev puas tsuaj rau cov hlab ntsws.
Cov ntaub ntawv saum toj no yog muab los ntawm:
Fahad I. Al-Saikhan, Mohamed A. Abd-Elaziz, Ramadan Al-Shdeifat, et al. Kev Npaj thiab Kev Ntsuam Xyuas ntawm Aviptadil Acetate Loaded PLGA Microparticles: Kev Kawm Ua Ntej los kho Pulmonary Hypertension. Latin American Journal of Pharmacy, 2022
Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Tshuaj, 2023
Multidimensional kev ua tau zoo ntawm kev txhim kho pulmonary ncig
Cov nyhuv vasodilation ntawm Aviptadil hauv lub ntsws yuav kawg ua tiav kev ua kom zoo dua ntawm cov hlab ntsws los ntawm ntau txoj hauv kev, kom ntseeg tau tias kev ua haujlwm ntawm pulmonary physiological functions.
Ua ntej, cov kev cai ntawm cov ntshav khiav nrawm ua kom cov ntshav khiav hauv lub ntsws thiab cov ntshav txaus rau cov ntaub so ntswg los ntawm kev ua kom zoo dua cov ntshav ntws los ntawm lub ntsws tom qab vasodilation. Qhov no tsis yog tsuas yog zam kom tsis txhob qeeb thiab tsis khov ntshav los ntawm vascular stenosis, tab sis tseem tiv thaiv kev cuam tshuam ntawm cov dej ntws ntau dhau ntawm phab ntsa ntawm cov hlab ntsha.
Secondly, optimization ntawm alveolar ntshav perfusion. Raws li qhov chaw tseem ceeb ntawm lub ntsws pauv roj, cov ntshav perfusion hauv alveoli ncaj qha cuam tshuam rau kev ua haujlwm ntawm kev sib pauv roj. Cov tshuaj no dilates pulmonary capillaries, nce ntshav perfusion nyob ib ncig ntawm alveoli, txhim khu kev ua tau zoo ntawm oxygen thiab carbon dioxide pauv ntawm alveoli thiab ntshav, txhim kho lub ntsws oxygenation muaj nuj nqi, thiab txhawb kev tshem tawm cov metabolic pov tseg nyob rau hauv lub ntsws, tswj physiological homeostasis nyob rau hauv lub ntsws.
Thaum kawg, kev sib koom ua ke ntawm pulmonary ncig thiab kev so ntawm cov hlab ntsha pulmonary tuaj yeem tswj hwm qhov sib npaug ntawm lub cev thiab cov hlab ntsws, txo cov teeb meem xws li kab mob hauv lub cev los ntawm pulmonary arterial hypertension, xyuas kom muaj kev sib koom tes ntawm cov ntshav ncig, thiab muab kev lees paub rau tag nrho lub cev kev ua haujlwm.
Cov ntaub ntawv saum toj no yog muab los ntawm:
Pulido T, Adzerikho I, Channick RN, et al. Macitentan thiab morbidity thiab tuag hauv pulmonary arterial hypertension. N Engl J Med, 2013, 369(9): 809-818
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Kev sib xyaw ua ke nrog qhov ncauj Treprostinil rau Pulmonary Arterial Hypertension. Am J Respir Crit Care Med, 2020, 201(6): 707-717
Cov ntaub ntawv
Keijzers GB. Aviptadil (Sena Tek). Kev xav tam sim no hauv Kev Tshawb Fawb Tshuaj, 2001, 2(4): 545-549
Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil kho rau pulmonary arterial hypertension. Ntawv Moo Zoo, 2009, 119(22): 2894-2903
Galie N, Barberà JA, Frost AE, et al. Kev Siv Ambrisentan ntxiv rau Tadalafil hauv Pulmonary Arterial Hypertension. N Engl J Med, 2015, 373(9): 834-844
Huang X, Balasubramanian A, Moutchia J, et al. Ambient Air Pollution Exposure and Mortality in the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc, 2025, 22(9): 1351-
FAQ
- Dab tsi yog aviptadil siv los kho?
Aviptadil, ib daim ntawv hluavtaws ntawm VIP, tseem hu ua RLF-100, yog tam sim no nyob rau theem II / III kev sim tshuaj. Cov tshuaj no tau raug xaiv los ua cov tshuaj menyuam ntsuag los ntawm FDA thiab tau siv yav dhau los los kho cov kab mob ua pa ntawm txoj hlab pa, xws li mob hawb pob, mob ntsws ntsws ntev (COPD), ARDS, thiab sarcoidosis.
- Puas yog aviptadil yog tshuaj tua kab mob?
Cov txiaj ntsig ua ntej ntawm COVID-Kev sim AIV, uas tau nrhiav cov neeg mob nrog COVID-19 thiab ua pa tsis ua haujlwm, qhia tau hais tias muaj txiaj ntsig zoo los tiv thaiv kab mob ntawm cov tshuaj tua kab mob hauv lub cev ntawm aviptadil.
- Nws siv sijhawm ntev npaum li cas rau aviptadil ua haujlwm?
Hnub 28, kev txhim kho hauv cov kev tshawb pom hluav taws xob ntawm cov pab pawg aviptadil yog qhov tseem ceeb tshaj plaws piv rau pawg placebo. Qhov no qhia txog qhov tseem ceeb ntawm kev nqus pa aviptadil.
Cim npe nrov: txhaj tshuaj aveptadil, lwm tus neeg, manufacturers, hoobkas, lag luam wholesale, yuav, nqe, tej, kev muag khoom